Trial Profile

Thorough QT/QTc trial of RPC 1063 in volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ozanimod (Primary)
Indications Multiple sclerosis; Ulcerative colitis
Focus Adverse reactions
Acronyms TQT

Most Recent Events

28 Oct 2017 Results of analysis assessing cardiac safety of ozanimod in RADIANCE and QT/QTc trials (see CTP 239937) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
24 Dec 2013 New trial record
05 Jun 2013 Primary endpoint `No significant difference between RPC 1063 and placebo in prolongation of corrected QT interval' has been met, according to a Receptos media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com